Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doubase C versus hydroxychloroquine + azithromycin for mild to moderate hospitalized COVID-19 in Kinshasa
ISRCTN16254682Phase 3Completed
- Sponsor
- Creppat Laboratories
- Start
- May 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Doubase C with Hydroxychloroquine + azithromycin (2 arms). Primary endpoint: Clinical worsening to severe COVID-19. Started May 2021; status: completed.
02
Drugs
Doubase Chydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN16254682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16254682.